Papers
5
Total Citations
775
H-Index
5
About
Martin Corsten is a leading head and neck surgical oncologist whose research focuses on optimizing treatment for oropharyngeal squamous cell carcinoma (OPSCC), particularly in the context of rising HPV-related cases. His major contribution is the landmark ORATOR trial, a phase 2 randomized study comparing primary radiotherapy (RT) versus transoral robotic surgery (TORS) with neck dissection for early-stage OPSCC. The initial 2019 results, cited over 458 times, provided critical comparative effectiveness data, while the 2024 final outcomes (37 citations) solidified long-term insights. Corsten also authored a seminal systematic review (134 citations) on TORS outcomes, establishing functional and surgical benchmarks. Notably, his work on developing Canada’s first TORS program (5 citations) addressed unique barriers to adopting robotic surgery in a single-payer system, demonstrating leadership in translating innovation into clinical practice. With over 775 total citations, Corsten’s research directly informs evidence-based decision-making for patients and surgeons, balancing oncologic control with quality of life. His contributions are pivotal for clinicians navigating the evolving landscape of minimally invasive head and neck cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5Development of a transoral robotic surgery program in Canada5 citations · 2013